---
title: V4:E07:S03 - Linezolid 69-Year-Old
created: 2024-06-21 21:44:52.717012
updated: 2025-01-15 23:13:22.961621
source: ChatGPT
source_file: conversations-004.json
conversation_id: dcc30bc5-ce29-4a41-bc5a-955ee7f8aa57
message_count: 4
tags:
- linezolid
- year
- source/chatgpt
- status/raw
- antibiotic-side-effects
- gut-health
- infection-risk
category:
- antibiotics
- side effects
- gut health
summary: Prolonged linezolid treatment may lead to replacement of normal gut flora
  by pathogenic microorganisms.
keypoints:
- partial loss of normal gut flora
- replacement by opportunistic pathogens
- reversible thrombocytopenia
- anaemia and neutropenia associated with linezolid therapy
monomyth_stage: "06 - Tests, Allies, Enemies"
gameboard_position: ''
truth_score: 80
entropy_score: Low
tone:
  sentiment: Neutral
  emotions:
  - informational
  - cautionary
  - neutral
  sycophancy_level: None
  notes: ''
related_events: []
syndication_status:
  arnie: false
  chris: false
  redmond: false
  clint: false
  pilot: false
ma5_inheritance: None
pre_silicon: false
voice_print: false
codex_candidate: false
phase: ''
enriched_date: '2026-04-09'
---

# V4:E07:S03 - Linezolid 69-Year-Old

> Exported from ChatGPT | 2024-06-21 | 4 messages

---

**You:**

What are the emotional, gut and common side effects after finishing a 10 day antibiotic treatment of linezolid for a 69 year old male Caucasian?

---

**ChatGPT:**

```json
{"query": "emotional, gut, and common side effects after finishing 10 day antibiotic treatment of linezolid in a 69 year old male Caucasian"}
```

---

**[Tool]:**

{"items":[{"paper_title":"Impact of prolonged treatment with linezolid on the human gut flora.","abstract":"A 79-year-old male was treated for 6 months with linezolid for prosthetic knee joint osteomyelitis. At the end of this 6-month period, quantitative stool cultures revealed partial loss of the normal gut flora and concomitant colonization by opportunistic pathogens such as Pseudomonas aeruginosa and other Gram-negatives. Follow-up cultures at 6 weeks after antibiotic discontinuation revealed restoration of the normal flora. Prolonged linezolid administration may lead to replacement of normal gut flora by pathogenic microorganisms, which under certain conditions might cause systemic infections.","paper_authors":["D. Kofteridis","P. Malliotakis","S. Maraki","M. Christofaki","G. Samonis"],"paper_publish_year":2009,"publication_journal_name":"International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","consensus_paper_details_url":"https://consensus.app/papers/impact-prolonged-treatment-flora-kofteridis/634506c06232519795c0e8188aaf02f2/?utm_source=chatgpt","doi":"10.1016/j.ijid.2009.02.001","volume":"13 5","pages":"\n          e313-5\n        ","search_result_number":1},{"paper_title":"Safety and tolerability of linezolid.","abstract":"Clinical trials have shown that linezolid (600 mg twice daily in adults) is safe and generally well tolerated for up to 28 days. Drug-related adverse events, which are typically mild to moderate in intensity and of limited duration, include diarrhoea, nausea and headache in adults, and diarrhoea, loose stools and vomiting in children. Clostridium difficile-related complications with linezolid are uncommon. Linezolid is a weak, reversible monoamine oxidase inhibitor: foods containing high concentrations of tyramine should be avoided, and linezolid should be used with caution in patients taking adrenergic or serotonergic agents or in those with uncontrolled hypertension. In the majority of patients, linezolid has minimal adverse effects on blood chemistry or haematology. There have been case reports of reversible thrombocytopenia, anaemia and neutropenia associated with linezolid therapy. In Phase III studies, 2.4% of patients treated with linezolid and 1.5% of patients treated with comparator drugs developed reversible thrombocytopenia (P = 0.066), but there was no evidence of an increased risk of agranulocytosis, aplastic anaemia or other irreversible blood dyscrasias. Reduced platelet counts were associated with linezolid treatment for >/=2 weeks; complete blood counts should be monitored weekly in patients receiving linezolid for more than 14 days and treatment should be discontinued if there is evidence of myelosuppression.","paper_authors":["G. French"],"paper_publish_year":2003,"publication_journal_name":"The Journal of antimicrobial chemotherapy","consensus_paper_details_url":"https://consensus.app/papers/safety-tolerability-linezolid-french/dd9f04d9403456d793ac8764091fa2f5/?utm_source=chatgpt","doi":"10.1093/JAC/DKG253","volume":"51 Suppl 2","pages":"\n          ii45-53\n        ","search_result_number":2},{"paper_title":"Good Clinical Outcomes but High Rates of Adverse Reactions during Linezolid Therapy for Serious Infections: a Proposed Protocol for Monitoring Therapy in Complex Patients","abstract":"ABSTRACT We assessed the toxicity and clinical outcomes associated with linezolid therapy (mean duration, 29 ± 28 days; range, 8 to 185 days) in 44 patients with serious gram-positive infections. Although a clinical cure was achieved in 73% of the cases, 28/44 (64%) had adverse reactions (thrombocytopenia, n = 13; anemia, n = 7; gastrointestinal, n = 12; peripheral neuropathy, n = 1; serotonin syndrome, n = 1), such that a systematic monitoring protocol was developed.","paper_authors":["E. Bishop","Sharmila Melvani","B. Howden","P. Charles","M. Grayson"],"paper_publish_year":2006,"publication_journal_name":"Antimicrobial Agents and Chemotherapy","consensus_paper_details_url":"https://consensus.app/papers/clinical-outcomes-high-rates-adverse-reactions-linezolid-bishop/72897bb88b065e4d9e1bf992cf9e8544/?utm_source=chatgpt","doi":"10.1128/AAC.50.4.1599-1602.2006","volume":"50","pages":"1599 - 1602","search_result_number":3},{"paper_title":"Linezolid for the treatment of infections caused by Gram-positive pathogens in China.","abstract":"In this randomised, double-blind, comparator-controlled, multicentre study conducted in China, 142 hospitalised patients aged 18-75 years with pneumonia (n=80) or complicated skin and soft-tissue infection (cSSTI) (n=62) due to suspected or known Gram-positive pathogens were randomised (1:1) to receive either linezolid 600mg (n=71) or vancomycin 1g in patients aged < or =60 years or 0.75g in patients aged >60 years (n=71) intravenously every 12h. The duration of treatment was 10-21 days for patients with pneumonia and 7-21 days for patients with cSSTI. Clinical outcomes were assessed at end-of-treatment (EOT) visit and follow-up (FU) visit 7-28 days post therapy. Staphylococcus aureus was the most common pathogen at baseline and most of these isolates were resistant to meticillin. All isolates were susceptible to linezolid and vancomycin. For the evaluable patients, the effective treatment rate for linezolid was higher than that for vancomycin at EOT (86.9% (53/61) vs. 61.7% (37/60)) and at FU (83.1% (49/59) vs. 64.9% (37/57)). Pathogen eradication rates for the microbiologically evaluable patients at FU were 79.2% (42/53) for linezolid and 61.5% (32/52) for vancomycin. The incidence of drug-related adverse events (AEs) was 25.4% (18/71) for linezolid and 16.9% (12/71) for vancomycin. Four (5.6%) linezolid-treated and eight (11.3%) vancomycin-treated patients discontinued the study drug because of an AE. Linezolid was well tolerated and effective for the treatment of infections caused by Gram-positive pathogens, including meticillin-resistant S. aureus.","paper_authors":["D. Lin","Ying-yuan Zhang","Ju-fang Wu","Fu Wang","Jing Zheng","J. Miao","Li Zheng","R. Sheng","Xin Zhou","Hua-Hao Shen","M. Ijzerman","R. Croos-Dabrera","Wei Sheng"],"paper_publish_year":2008,"publication_journal_name":"International journal of antimicrobial agents","consensus_paper_details_url":"https://consensus.app/papers/linezolid-treatment-infections-caused-pathogens-china-lin/7638204af42d53c8a93dc5e6486ebcb6/?utm_source=chatgpt","doi":"10.1016/j.ijantimicag.2008.04.004","volume":"32 3","pages":"\n          241-9\n        ","search_result_number":4},{"paper_title":"Use of linezolid in infants and children: a retrospective multicentre study of the Italian Society for Paediatric Infectious Diseases.","abstract":"OBJECTIVES\nBecause of the spread of drug-resistant Gram-positive bacteria, the use of linezolid for treating severe infections is increasing. However, clinical experience in the paediatric population is still limited. We undertook a multicentre study to analyse the use of linezolid in children.\n\n\nMETHODS\nHospitalized children treated with linezolid for a suspected or proven Gram-positive or mycobacterial infection were analysed retrospectively. Side effects were investigated, focusing on younger children and long-term treatments.\n\n\nRESULTS\nSeventy-five patients (mean age 6.8 years, range 7 days to 17 years) were studied. Mean ± SD linezolid treatment duration was 26.13 ± 17 days. Clinical cure was achieved in 74.7% of patients. The most frequent adverse events were diarrhoea and vomiting. Two patients had severe anaemia, two neutropenia and one thrombocytopenia. Two cases of grade 3 liver function test elevation and one case of pancreatitis were reported. The overall frequency of adverse events was similar between patients treated for >28 days and those receiving shorter treatments (30.8% versus 28.6%, P = 0.84). Children aged <2 years received linezolid for a shorter duration than older children (21.2 days versus 28.4 days, P = 0.05), whereas the frequency of adverse events was similar in the two age groups.\n\n\nCONCLUSIONS\nIn our paediatric population, linezolid appeared safe and effective for the treatment of selected Gram-positive and mycobacterial infections. The adverse reactions encountered were reversible and appeared comparable to those reported in paediatric clinical trials. Nevertheless, the potential for haematological toxicity of linezolid in children means that careful monitoring is required during treatment.","paper_authors":["S. Garazzino","A. Krzysztofiak","S. Esposito","E. Castagnola","A. Plebani","L. Galli","M. Cellini","R. Lipreri","C. Scolfaro","C. Bertaina","C. Calitri","E. Bozzola","L. Lancella","A. Quondamcarlo","S. Bosis","L. Pugni","G. Losurdo","A. Soresina","M. de Gaudio","I. Mariotti","L. Mancini","C. Gabiano","P. Tovo"],"paper_publish_year":2011,"publication_journal_name":"The Journal of antimicrobial chemotherapy","consensus_paper_details_url":"https://consensus.app/papers/infants-children-retrospective-multicentre-study-garazzino/6f10d709cb225ce4b375cf4b02d0e53f/?utm_source=chatgpt","doi":"10.1093/jac/dkr285","volume":"66 10","pages":"\n          2393-7\n        ","search_result_number":5},{"paper_title":"Probable Linezolid-Induced Thrombocytopenia in a Patient With Vancomycin-Resistant Enterococci","abstract":"Purpose: A probable case of linezolid-induced thrombocytopenia is reported. Summary: A 74-year-old Caucasian male with renal dysfunction was diagnosed with diverticulosis. Patient was prescribed linezolid 600 mg orally twice daily for vancomycin-resistant enterococci abdominal infection that developed secondary to colon resection. Upon initiation of linezolid, platelet count dropped from 248 000 cells/mm3 on day 1 to 97 000 cells/mm3 on day 5 of treatment. Linezolid was discontinued and platelet counts improved to pretreatment levels. Application of the Naranjo probability scale indicated a probable association of linezolid therapy and thrombocytopenia. Clinicians should be aware that linezolid has this hematologic side effect and that patients with renal dysfunction are at increased risk. Monitoring platelet count more than once weekly should be advisable in these patients. Conclusion: A 74-year-old Caucasian male with renal dysfunction developed a probable case of linezolid-induced thrombocytopenia after receiving the drug for 5 days for treatment of vancomycin-resistant enterococci abdominal infection.","paper_authors":["M. Poulakos","Y. Grace","C. Coakley"],"paper_publish_year":2012,"publication_journal_name":"Journal of Pharmacy Practice","consensus_paper_details_url":"https://consensus.app/papers/linezolidinduced-thrombocytopenia-patient-with-poulakos/ca6ca079d28f5e928bfa65b344821616/?utm_source=chatgpt","doi":"10.1177/0897190012442720","volume":"25","pages":"615 - 618","search_result_number":6},{"paper_title":"Compassionate Use of Contezolid for the Treatment of Tuberculous Pleurisy in a Patient with a Leadless Pacemaker","abstract":"Abstract We report the case of an 87-year-old woman with tuberculous pleurisy. She developed adverse effects in the form of thrombocytopenia and gastrointestinal hemorrhage with isoniazid, and thrombocytopenia with linezolid. Her treatment was switched to contezolid plus cycloserine for a 4-week antibiotic duration, with a favorable outcome.","paper_authors":["Yi-xin Kang","Cheng Ge","Huan-Xia Zhang","Saizhe Liu","H. Guo","J. Cui"],"paper_publish_year":2022,"publication_journal_name":"Infection and Drug Resistance","consensus_paper_details_url":"https://consensus.app/papers/compassionate-contezolid-treatment-tuberculous-kang/9f7c5e6b64f65cfea2aac65473e6cae8/?utm_source=chatgpt","doi":"10.2147/IDR.S373082","volume":"15","pages":"4467 - 4470","search_result_number":7},{"paper_title":"Safety of linezolid, rifampicin, and clindamycin combination therapy in patients with prosthetic joint infection.","abstract":"We investigated adverse events in patients with prosthetic joint infections receiving combination therapy with linezolid, rifampicin, and clindamycin for ≥ 7 days. Twenty-two patients were evaluated. The combination therapy was administered for 15.5 (7-29) days at dosages of 1200, 450, and 450-1200 mg/day for linezolid, rifampicin, and clindamycin, respectively. Adverse events (gastrointestinal, eye, and skin disorders; liver damage; myelosuppression; hyponatremia, and others) were recorded. The incidence rates of leukopenia, neutropenia, anemia, thrombocytopenia, and hyponatremia were 36.4%, 31.8%, 40.9%, 18.2%, and 18.2%, respectively. Common Terminology Criteria for Adverse Events version 5.0 Grade 3 neutropenia, anemia, and hyponatremia were observed. The incidence rate of myelosuppression was higher following combination therapy compared with that previously reported following single-drug administration. All patients were discharged after the infection was under control. It is important to monitor these adverse events during combination therapy with the aforementioned agents; these conditions may be relieved by discontinuing linezolid.","paper_authors":["Shunsuke Kobayashi","Seiji Tagawa","T. Ogura","Akira Kitaoka","T. Yasu"],"paper_publish_year":2022,"publication_journal_name":"Drug discoveries & therapeutics","consensus_paper_details_url":"https://consensus.app/papers/safety-rifampicin-clindamycin-combination-therapy-kobayashi/6f57ffdf2ab65b66bd520d118c161ca0/?utm_source=chatgpt","doi":"10.5582/ddt.2022.01038","volume":"","pages":"","search_result_number":8},{"paper_title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.","abstract":"Linezolid, the first available member of a new antibiotic class, the oxazolidinones, is broadly active against gram-positive bacteria, including drug-resistant strains. In this randomized, open-label trial, hospitalized adults with known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with linezolid (600 mg twice daily; n=240) or vancomycin (1 g twice daily; n=220) for 7-28 days. S. aureus was isolated from 53% of patients; 93% of these isolates were MRSA. Skin and soft-tissue infection was the most common diagnosis, followed by pneumonia and urinary tract infection. At the test-of-cure visit (15-21 days after the end of therapy), among evaluable patients with MRSA, there was no statistical difference between the 2 treatment groups with respect to clinical cure rates (73.2% of patients in the linezolid group and 73.1% in the vancomycin group) or microbiological success rates (58.9% in the linezolid group and 63.2% in the vancomycin group). Both regimens were well tolerated, with similar rates of adverse events.","paper_authors":["D. Stevens","D. Herr","H. Lampiris","J. Hunt","D. Batts","B. Hafkin"],"paper_publish_year":2002,"publication_journal_name":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","consensus_paper_details_url":"https://consensus.app/papers/linezolid-versus-vancomycin-treatment-staphylococcus-stevens/1d20fd99162b5a2fac6dd588b6942012/?utm_source=chatgpt","doi":"10.1086/340353","volume":"34 11","pages":"\n          1481-90\n        ","search_result_number":9},{"paper_title":"Serotonin Toxicity Associated with Concomitant Use of Linezolid","abstract":"OBJECTIVE: To report 2 cases of serotonin toxicity (ST) associated with concomitant use of linezolid and serotonergic drugs and review previously published case reports. CASE SUMMARIES: Case 1. A 38-year-old white female with cystic fibrosis treated with venlafaxine 300 mg/day for one year was prescribed linezolid 600 mg intravenously every 12 hours for treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection. She displayed symptoms of ST 8 days after the introduction of linezolid. The venlafaxine dosage was decreased to 150 mg/day, and symptoms gradually abated over 36 hours. Case 2. A 37-year-old male with multiple myeloma received citalopram 40 mg/day and trazodone 150 mg/day for anxiety-related disorders. Linezolid treatment with 600 mg orally twice daily was instituted for MRSA cellulitis. The following day, the patient developed anxiety, panic attacks, tremors, tachycardia, and hypertension that persisted throughout linezolid treatment. Symptoms finally waned 5 days after linezolid treatment was stopped. DISCUSSION: The symptoms observed in our patients were consistent with Sternbach's criteria for ST. A review of published case reports showed a short time to onset of symptoms following the introduction of linezolid, generally within 1–3 days. Also of note is the use of relatively high dosages of serotonergic drugs. Use of the Naranjo probability scale indicated a possible relationship between the use of linezolid and the occurrence of ST in both cases. CONCLUSIONS: Clinicians should pay special attention to patients treated with serotonergic drugs, especially those receiving dosages in the higher end of the normal range who are prescribed linezolid, and consider tapering or reducing the dosage of serotonergic drugs for the duration of antibiotic therapy.","paper_authors":["L. Bergeron","M. Boulé","S. Perreault"],"paper_publish_year":2005,"publication_journal_name":"Annals of Pharmacotherapy","consensus_paper_details_url":"https://consensus.app/papers/serotonin-toxicity-associated-concomitant-linezolid-bergeron/9448fe950db45b0bbbda698b85826d44/?utm_source=chatgpt","doi":"10.1345/aph.1E523","volume":"39","pages":"956 - 961","search_result_number":10},{"paper_title":"Hematologic effects of linezolid in young children","abstract":"Background. Linezolid is an effective and well-tolerated antibiotic for the treatment of Gram-positive infections, including hospital and community-acquired pneumonia and complicated and uncomplicated skin and skin structure infections. In adults linezolid treatment for ≥2 weeks has been associated with reversible hematopoietic suppression, primarily thrombocytopenia. Objective. To evaluate the occurrence of hematologic effects in children with Gram-positive infections in an open label study of linezolid vs. vancomycin. Methods. Detailed analyses of hematologic data, including reported hematologic adverse events, complete blood counts, reticulocyte index (RI) and iron studies (serum iron and transferrin saturation), were conducted in both groups at baseline and during and after treatment with the use of an intent-to-treat analysis. Results. Three hundred sixteen patients (median age, 1.65 yr) randomized 2:1 to linezolid (n = 215) or vancomycin (n = 101) were treated. Total treatment durations were similar in the vancomycin group (12.2 ± 6.4 days; median, 11.0 days) and the linezolid group (11.3 ± 5.0 days; median, 11.0 days) (P = 0.20). No significant differences were noted in drug-related hematologic events, such as thrombocytopenia (linezolid, 1.9%vs. vancomycin, 0%; P = 0.170), anemia (linezolid, 1.4%vs. vancomycin, 1.0%; P = 0.771) or neutropenia (linezolid, 0%vs. vancomycin, 0%). Hemoglobin values also were similar between treatment groups when assessed by shifts from baseline to lowest recorded value. Frequency of occurrence of any substantially abnormal value for hemoglobin (15.7%vs. 12.4%), platelets (12.9%vs. 13.4%) and neutrophils (5.9%vs. 4.3%) were similar in the linezolid and vancomycin groups. No clinically relevant changes in RI or iron studies were noted between treatment groups, and parallel increases in RI occurred with both linezolid and vancomycin. Conclusions. No significant differences in hematologic profiles between linezolid and vancomycin occurred in this pediatric population.","paper_authors":["H. Meissner","T. Townsend","W. Wenman","S. Kaplan","M. Morfin","Barbara Edge-Padbury","J. Bruss"],"paper_publish_year":2003,"publication_journal_name":"The Pediatric Infectious Disease Journal","consensus_paper_details_url":"https://consensus.app/papers/hematologic-effects-children-meissner/7d6c21f58bfa5b1b88ebca4ea3db33c2/?utm_source=chatgpt","doi":"10.1097/01.inf.0000087021.20838.d9","volume":"22","pages":"S186-S192","search_result_number":11},{"paper_title":"Linezolid-induced interstitial nephritis in a kidney-transplant patient.","abstract":"Linezolid is a recent oral antibiotic used in drug-resistant Gram-positive cocci infections. Herein, we report on the first case of linezolid-related acute renal failure in a kidney-transplant patient. A 60-year-old male having autosomic polycystic kidney disease with liver involvement, on cyclosporin A, mycophenolate mofetil and very low dose prednisolone, presented with an Enterococcus faecium abscess of a huge liver cyst, which was treated by percutaneous drainage and linezolid therapy. Eight days after starting linezolid, he presented with acute renal failure, i.e. serum creatinine increased from 136- 221 micromol/l, associated with mild hypereosinophilia, anemia and thrombocytopenia. There was no skin rash, arthralgia, eosinophiluria or proteinuria. The transplant kidney biopsy, performed 15 days after the beginning of linezolid therapy, showed interstitial nephritis and focal tubular atrophy. After linezolid withdrawal and increasing prednisolone daily dose to 20 mg/d, within a few days, serum creatinine had decreased; after 2 and 4 weeks post linezolid withdrawal, his serum creatinine was 166 and 159 micromol/l, respectively. Because of the potential side effects of linezolid, i.e. myelosuppression and possibly nephrotoxicity, we recommend close monitoring of these parameters when linezolid therapy is attempted in kidney transplant patients.","paper_authors":["L. Esposito","N. Kamar","C. Guilbeau-Frugier","M. Mehrenberger","A. Modesto","L. Rostaing"],"paper_publish_year":2007,"publication_journal_name":"Clinical nephrology","consensus_paper_details_url":"https://consensus.app/papers/linezolidinduced-nephritis-kidneytransplant-patient-esposito/e36144782ef35f2ea23f5cbd557457ff/?utm_source=chatgpt","doi":"10.5414/CNP68327","volume":"68 5","pages":"\n          327-9\n        ","search_result_number":12},{"paper_title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.","abstract":"Linezolid was provided for treatment of multidrug-resistant, gram-positive infections through a compassionate-use program. Patients (n=796) received 600 mg of linezolid intravenously or orally every 12 h (828 treatment courses). Bacteremia was present in 46% of infections, endocarditis was present in 10.6%, and line-related infections were present in 31.1%. Other infections included intraabdominal infections (15.1%), complicated skin and skin-structure infections (13.3%), and osteomyelitis (10.7%). Causative pathogens included vancomycin-resistant enterococci (66.3%) and methicillin-resistant staphylococci (22.1%). Clinical intent-to-treat (ITT) outcomes in the evaluable population were as follows: cure, 73.3%; failure, 6.8%; and indeterminate, 19.9%. Microbiological ITT outcomes in evaluable patients were as follows: cure, 82.4%; failure, 14.1%; and indeterminate, 3.5%. At the test of cure assessment, the clinical cure and microbiological success rates were 91.5% and 85.8%, respectively. The most common adverse events possibly related to linezolid use were gastrointestinal disturbances (9.8% of cases), thrombocytopenia (7.4% of cases), decreased hemoglobin/hematocrit levels (4.1% of cases), and cutaneous reactions (4.0% of cases). Linezolid provided high rates of clinical cure and microbiological success in this complicated patient population, with very good overall tolerance.","paper_authors":["M. Birmingham","C. Rayner","A. Meagher","S. Flavin","D. Batts","Jerome J. Schentag"],"paper_publish_year":2003,"publication_journal_name":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","consensus_paper_details_url":"https://consensus.app/papers/linezolid-treatment-multidrugresistant-infections-birmingham/bacf0a19e2245d43a3f1e1e582616f90/?utm_source=chatgpt","doi":"10.1086/345744","volume":"36 2","pages":"\n          159-68\n        ","search_result_number":13},{"paper_title":"Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid","abstract":"ABSTRACT Thrombocytopenia is a common side effect of linezolid, an oxazolidinone antibiotic often used to treat multidrug-resistant Gram-positive bacterial infections. Various risk factors have been suggested, including linezolid dose and duration of therapy, baseline platelet counts, and renal dysfunction; still, the mechanisms behind this potentially treatment-limiting toxicity are largely unknown. A clinical study was conducted to investigate the relationship between linezolid pharmacokinetics and toxicodynamics and inform strategies to prevent and manage linezolid-associated toxicity. Forty-one patients received 42 separate treatment courses of linezolid (600 mg every 12 h). A new mechanism-based, population pharmacokinetic/toxicodynamic model was developed to describe the time course of plasma linezolid concentrations and platelets. A linezolid concentration of 8.06 mg/liter (101% between-patient variability) inhibited the synthesis of platelet precursor cells by 50%. Simulations predicted treatment durations of 5 and 7 days to carry a substantially lower risk than 10- to 28-day therapy for platelet nadirs of <100 ×109/liter. The risk for toxicity did not differ noticeably between 14 and 28 days of therapy and was significantly higher for patients with lower baseline platelet counts. Due to the increased risk of toxicity after longer durations of linezolid therapy and large between-patient variability, close monitoring of patients for development of toxicity is important. Dose individualization based on plasma linezolid concentration profiles and platelet counts should be considered to minimize linezolid-associated thrombocytopenia. Overall, oxazolidinone therapy over 5 to 7 days even at relatively high doses was predicted to be as safe as 10-day therapy of 600 mg linezolid every 12 h.","paper_authors":["L. Boak","C. Rayner","M. Grayson","D. Paterson","D. Spelman","S. Khumra","B. Capitano","A. Forrest","Jian Li","R. Nation","J. Bulitta"],"paper_publish_year":2014,"publication_journal_name":"Antimicrobial Agents and Chemotherapy","consensus_paper_details_url":"https://consensus.app/papers/population-pharmacokinetics-toxicodynamics-linezolid-boak/5533f1ad0eda5a8da0be93804089eeb6/?utm_source=chatgpt","doi":"10.1128/AAC.01885-13","volume":"58","pages":"2334 - 2343","search_result_number":14},{"paper_title":"Clinical experience with linezolid in the treatment of resistant gram-positive infections.","abstract":"This study presents our clinical experience with linezolid in 19 patients with serious resistant gram-positive infections enrolled as part of the compassionate study. In this prospective, non-randomized, noncomparative study, 19 patients were enrolled as part of the National Compassionate Study Protocol conducted by Pharmacia-Upjohn. At the time of this writing, these patients had not been published in the literature. All of the patients had to have documented evidence of serious gram-positive infections in normally sterile sites and should have been unable to tolerate available antimicrobial therapy or be unresponsive to available drugs. Clinical characteristics, laboratory values, and pharmacokinetic and pharmacodynamic parameters were obtained. Patients were followed both short-term and long-term after completion of therapy. Nineteen patients were enrolled: 13 females and 6 males. The average age was 63 years. The average length of therapy with linezolid was 22 days. Methicillin-resistant Staphylococcus aureus (MRSA) was treated in eight patients, methicillin-resistant Staphylococcus epidermidis (MRSE) in two patients, vancomycin-resistant Enterococcus faecium (VREF) in eight patients, and coagulase-negative Staphylococcus in two patients. Co-infecting organisms include Enterococcus species colonization in six patients, Pseudomonas species in one patient, Serratia marcenens in one patient, and Candida albicans in one patient. Sterile sites that were infected included bone and joint (wounds and septic joints) in six patients, gastrointestinal system (hepatobiliary, liver abscess, Crohn's) in five patients, genitourinary (kidney and urine) in two patients, blood in five patients, respiratory in one patient, and aortic valve in 1 patient. Linezolid was given at 600 mg IV every 12 hours with a mean length of therapy of 22 days. Surgical drainage was used in combination with linezolid in 11 of the patients. Seventy nine percent of these patients achieved clinical and microbiologic cure, and none of the deaths reported in this series were related to the drug. Adverse events included skin rash in one patient, mild bone marrow suppression in two patients, and mild elevation in liver function tests in two patients. No life-threatening adverse events were noted. It appears that linezolid, along with surgical intervention (when necessary), appears to be an effective treatment option for resistant gram-positive infections. Long-term studies evaluating the possible resistance rates are necessary.","paper_authors":["S. Antony","E. Diaz-Vasquez","C. Stratton"],"paper_publish_year":2001,"publication_journal_name":"Journal of the National Medical Association","consensus_paper_details_url":"https://consensus.app/papers/experience-treatment-infections-antony/d92f15b74c125901907e1f27580c2fe4/?utm_source=chatgpt","doi":"","volume":"93 10","pages":"\n          386-91\n        ","search_result_number":15},{"paper_title":"The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin.","abstract":"OBJECTIVE\nThe incidence of infections caused by methicillin-resistant Staphylococcus aureus continues to increase annually. Unfortunately, only a few therapeutic agents are available for the treatment of patients with such infections and all of the existing drugs have limitations. A pressing need exists, therefore, to identify new antibiotics for use in this clinical setting. The efficacy and safety of linezolid were studied in a compassionate use treatment programme and the results of treating a subset of patients with S. aureus infections are presented here.\n\n\nMETHODS\nPatients received linezolid in a dosage of 600 mg intravenously (iv) and/or orally twice daily. Clinical and bacteriological responses were assessed after a minimum of 7 days and following completion of therapy.\n\n\nRESULTS\nSeven hundred and ninety-six patients who suffered 828 episodes of infection were enrolled in the linezolid compassionate use protocol. Of these, 183 patients received linezolid for 191 infections caused by S. aureus; in 151 cases, patients were intolerant of vancomycin, had a mixed S. aureus/vancomycin-resistant enterococcal infection or had no iv access, and, in 40 cases, patients had failed to respond to treatment with vancomycin. The median age of the patients was 57 years (range 14-93 years) and 53.9% were female. The predominant sites of infection were as follows: bone or joint (27.2%); skin and skin structure (25.1%); bloodstream (20.9%); and lower respiratory tract (12.6%). The clinical success rates in the clinically evaluable and all-treated populations were 83.9% and 62.3%, respectively, whereas the bacteriological eradication rates were 76.9% and 70.2% in the bacteriologically evaluable and all-treated populations, respectively. Linezolid was well tolerated. In 76 (39.8%) of the 191 episodes of infection, patients experienced one or more adverse events or exhibited one or more abnormal laboratory results; in 35 (18.3%) of the 191 cases it was necessary to discontinue treatment. Gastrointestinal tract-related symptoms (nausea, vomiting and diarrhoea) were the most common possibly or probably related adverse events and the most common reasons for drug discontinuation.\n\n\nCONCLUSIONS\nLinezolid was effective and well tolerated in patients with S. aureus infections who were enrolled in this compassionate use protocol.","paper_authors":["P. Moise","A. Forrest","M. Birmingham","Jerome J. Schentag"],"paper_publish_year":2002,"publication_journal_name":"The Journal of antimicrobial chemotherapy","consensus_paper_details_url":"https://consensus.app/papers/efficacy-safety-treatment-staphylococcus-aureus-moise/4029d5d0e88b58d0872e00c4ddac346a/?utm_source=chatgpt","doi":"10.1093/JAC/DKF215","volume":"50 6","pages":"\n          1017-26\n        ","search_result_number":16},{"paper_title":"Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).","abstract":"We compared the health outcomes in patients treated with linezolid or vancomycin for complicated skin and soft tissue infections (cSSTIs). This analysis is part of a randomised, open-label, multinational trial involving 1200 adult patients hospitalised with cSSTIs due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Subjects received linezolid 600 mg intravenous (i.v.) or oral, or vancomycin 1g i.v. every 12 h. A test-of-cure was assessed at 7 days post therapy. Compared with vancomycin, linezolid treatment was associated with significantly shorter length of stay (all P < 0.01), decreased i.v. antibiotic treatment duration (all P < 0.0001) and higher discharge rates (all P < 0.05). Thus, linezolid has the potential to reduce medical resource use for the treatment of cSSTIs.","paper_authors":["K. Itani","J. Weigelt","Jim Z. Li","S. Duttagupta"],"paper_publish_year":2005,"publication_journal_name":"International journal of antimicrobial agents","consensus_paper_details_url":"https://consensus.app/papers/reduces-length-duration-treatment-compared-vancomycin-itani/4180edd4a4025a34acef2a30107c9c57/?utm_source=chatgpt","doi":"10.1016/J.IJANTIMICAG.2005.09.003","volume":"26 6","pages":"\n          442-8\n        ","search_result_number":17},{"paper_title":"Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.","abstract":"BACKGROUND\nResistant bacteria often complicate the management of skin and soft tissue infections of the lower extremities. This open-label study compared oral linezolid and intravenous vancomycin for management of complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA).\n\n\nMETHODS\nPatients aged 18 years or older with proven MRSA-related complicated skin and soft-tissue infections requiring surgical intervention were randomized to receive oral linezolid (n=30) or intravenous vancomycin (n=30) for 7 to 21 days. Clinical and microbiological outcomes, duration of hospitalization and drug treatment, and outpatient charges were determined.\n\n\nRESULTS\nLinezolid was associated with greater rates of clinical cure and improvement (P=.015), a 3-day shorter median length of stay (P=.003), and reduced outpatient charges (P<.001). Vancomycin therapy was associated with more treatment failures and subsequent lower-extremity amputations (P=.011).\n\n\nCONCLUSIONS\nClinical outcomes were significantly better with linezolid than with vancomycin. Additionally, linezolid was associated with reduced length of stay and outpatient charges.","paper_authors":["J. Sharpe","E. Shively","H. Polk"],"paper_publish_year":2005,"publication_journal_name":"American journal of surgery","consensus_paper_details_url":"https://consensus.app/papers/outcomes-versus-vancomycin-treatment-mrsacomplicated-sharpe/7df9e1cb72445d9989747e35edffa256/?utm_source=chatgpt","doi":"10.1016/J.AMJSURG.2005.01.011","volume":"189 4","pages":"\n          425-8\n        ","search_result_number":18},{"paper_title":"Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.","abstract":"We report our experience with linezolid in an investigation of its use against resistant gram-positive bacterial infections. Fifteen patients who had renal failure (n=6), recent liver transplantation (n=5) or surgery (n=6), cancer (n=3), endocarditis (n=2), or human immunodeficiency virus infection (n=1), along with infections due to vancomycin-resistant enterococcus (VRE), and 2 patients with infections due to methicillin-resistant Staphylococcus species who had adverse reactions to vancomycin were treated with linezolid (600 mg every 12 h for 5-42 days (mean+/-SD, 20.5+/-3.5 days). Abscess drainage or prosthetic device removal was undertaken. Microbiological cure occurred in all 10 patients who completed therapy, and all 7 patients alive at follow-up were free of infection. No deaths were attributable to the index infection. Adverse events associated with linezolid use were mild leukopenia in 1 patient and nausea in another. It appears that administration of linezolid, in conjunction with surgical intervention or device removal, is an effective treatment option for serious resistant gram-positive bacterial infections.","paper_authors":["J. Chien","M. Kucia","R. Salata"],"paper_publish_year":2000,"publication_journal_name":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","consensus_paper_details_url":"https://consensus.app/papers/oxazolidinone-treatment-infections-chien/114a992de27a5db5bc3f9eccaa57bcf2/?utm_source=chatgpt","doi":"10.1086/313597","volume":"30 1","pages":"\n          146-51\n        ","search_result_number":19},{"paper_title":"Prolonged use of linezolid in bone and joint infections: a retrospective analysis of adverse effects","abstract":"Abstract Objectives Antibiotic treatment for bone and joint infections generally lasts for 6 weeks or longer. Linezolid may be a good option for treating bone and joint infections, but there is an increased risk of potential serious adverse drug events (ADEs) when used for more than 28 days. The aim of this study was to obtain detailed information on the type and time to occurrence of the patient-reported ADEs, the dynamics of haematopoiesis over time, and the reasons for early discontinuation of linezolid when used for an intended maximum duration of 12 weeks. Methods This single-centre retrospective study was conducted at the Sint Maartenskliniek in The Netherlands. Patients were included if they were planned to use linezolid for more than 28 days. The main reason for discontinuation of linezolid, the ADE according to the Naranjo score, and the time to occurrence of ADEs were analysed. Results Among 78 patients, drug toxicity led to early discontinuation of linezolid in 11 (14%) patients before and nine (12%) after 28 days of therapy. The median treatment duration was 42 days. Gastrointestinal intolerance (42%) and malaise (32%) were the most common ADEs. In 75% of the cases the ADE occurred within 28 days of therapy. Sixty-seven patients were able to continue linezolid beyond 28 days, 87% of whom completed therapy as scheduled. Severe cytopenia, according to the Common Terminology Criteria for Adverse events (CTCA), was observed in four patients and was reversible after discontinuation of linezolid. One patient suffered optic neuropathy related to linezolid use. Conclusions Linezolid could be considered an alternative option to the current standard of IV glycopeptides for the treatment of bone and joint infection for up to 12 weeks. If patients pass the first 28 days of therapy, the likelihood of successful completion of therapy is high with a low risk of serious ADEs.","paper_authors":["Karin Veerman","Jon Goosen","Karin Spijkers","N. Jager","Petra Heesterbeek","Denise Telgt"],"paper_publish_year":2023,"publication_journal_name":"Journal of Antimicrobial Chemotherapy","consensus_paper_details_url":"https://consensus.app/papers/prolonged-linezolid-bone-joint-infections-retrospective-veerman/8e4abf1ca2fb54c6b2d7a3e2be026f2a/?utm_source=chatgpt","doi":"10.1093/jac/dkad276","volume":"78","pages":"2660 - 2666","search_result_number":20}]}

---

**ChatGPT:**

### Introduction

Linezolid, an antibiotic used to treat serious bacterial infections, can have various side effects after a 10-day course of treatment, especially in an older adult.

### Evidence

1. **Emotional Side Effects**
   - Emotional and psychiatric side effects are rare but possible. Some patients might experience symptoms such as confusion or serotonin syndrome, particularly if they are on other serotonergic medications [(Bergeron et al., 2005)](https://consensus.app/papers/serotonin-toxicity-associated-concomitant-linezolid-bergeron/9448fe950db45b0bbbda698b85826d44/?utm_source=chatgpt).

2. **Gut Side Effects**
   - Common gastrointestinal side effects include diarrhea, nausea, and vomiting. These are usually mild to moderate in intensity and of limited duration [(French, 2003)](https://consensus.app/papers/safety-tolerability-linezolid-french/dd9f04d9403456d793ac8764091fa2f5/?utm_source=chatgpt), [(Lin et al., 2008)](https://consensus.app/papers/linezolid-treatment-infections-caused-pathogens-china-lin/7638204af42d53c8a93dc5e6486ebcb6/?utm_source=chatgpt).
   - There can also be alterations in gut flora, with potential overgrowth of opportunistic pathogens like Pseudomonas aeruginosa, especially after prolonged use [(Kofteridis et al., 2009)](https://consensus.app/papers/impact-prolonged-treatment-flora-kofteridis/634506c06232519795c0e8188aaf02f2/?utm_source=chatgpt).

3. **Common Side Effects**
   - **Hematologic**: Thrombocytopenia (a drop in platelet count) is a significant concern, especially with extended treatment durations. It can occur as early as five days into treatment and is generally reversible after discontinuation [(Bishop et al., 2006)](https://consensus.app/papers/clinical-outcomes-high-rates-adverse-reactions-linezolid-bishop/72897bb88b065e4d9e1bf992cf9e8544/?utm_source=chatgpt), [(Boak et al., 2014)](https://consensus.app/papers/population-pharmacokinetics-toxicodynamics-linezolid-boak/5533f1ad0eda5a8da0be93804089eeb6/?utm_source=chatgpt).
   - **Myelosuppression**: This includes anemia and neutropenia, which require regular monitoring of blood counts [(French, 2003)](https://consensus.app/papers/safety-tolerability-linezolid-french/dd9f04d9403456d793ac8764091fa2f5/?utm_source=chatgpt).
   - **Neuropathy**: Peripheral neuropathy is another reported side effect, although it is less common and typically associated with longer-term use [(Bishop et al., 2006)](https://consensus.app/papers/clinical-outcomes-high-rates-adverse-reactions-linezolid-bishop/72897bb88b065e4d9e1bf992cf9e8544/?utm_source=chatgpt).

### Conclusion

A 69-year-old male completing a 10-day course of linezolid might experience gastrointestinal issues (diarrhea, nausea, vomiting), potential changes in gut flora, and hematologic side effects like thrombocytopenia. Emotional side effects are less common but possible, particularly if the patient is on other serotonergic drugs. Regular monitoring of blood counts during treatment is advised.

Like our GPT? Try our full AI-powered search engine and academic features for free at [consensus.app](https://consensus.app/?utm_source=chatgpt).

---